SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca’s ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsight

The SERD market is expected to grow significantly due to factors like improved diagnosis, treatment advancements, demographics, increased awareness, and supportive regulations in the 7MM. Additionally, the recent approvals of SERD drugs such as AstraZeneca’s ETCAMAH (camizestrant) and pipeline activity of emerging therapies including Palazestrant (Olema Pharmaceuticals), Giredestrant (Roche), Borestrant (EnhancedBio/Zenopharm), D-0502 (Inventis Bio), and others are expected to fuel the market of SERD by 2036.

LAS VEGAS, Oct. 5, 2026 /PRNewswire/ — DelveInsight’s SERD Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as ER+/HER2- breast cancer, Endometrial cancer, HER2+ breast cancer, Ovarian cancer, ESR1 mutated breast cancer, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging SERD drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets (the US, EU4, UK, and Japan).

Key Takeaways from the SERD Market Report

• The total SERD market size is expected to grow positively by 2036 in the leading markets.
• The United States accounted for the largest SERD market size of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• The report provides the total potential number of patients in the indications, such as ER+/HER2- breast cancer, Endometrial cancer, HER2+ breast cancer, Ovarian cancer, ESR1 mutated breast cancer, and others.
• HR+/HER2- breast cancer is one of the leading target indication for use of SERDs in the 7MM with total cases of nearly 485,000 in 2025, which is expected to increase by 2036 in the 7MM.
• Leading SERD companies, such as Olema Pharmaceuticals, Roche, EnhancedBio, Zenopharm, Inventis Bio, Atossa Therapeutics, Hengrui Medicine, Simcere, Kind Pharmaceuticals, and others, are developing novel SERD drugs that can be available in the SERD market in the coming years. 
• Some of the key SERD drugs in clinical trials include Palazestrant, Giredestrant, Borestrant, D-0502, (Z)-Endoxifen, HRS-8080, SIM0270, AND019, and others.

Discover what patient populations may benefit most from treatment with oral SERDs @ https://www.delveinsight.com/report-store/serd-market-forecast

Key Factors Driving the SERD Market 

• Rising Prevalence of Hormone Receptor-Positive Breast Cancer: The growing incidence of estrogen receptor-positive (ER+) breast cancer is increasing the demand for effective endocrine therapies. SERDs directly target estrogen receptor signaling, creating a strong addressable patient population.
• Increasing Resistance to Existing Endocrine Therapies: Acquired resistance to aromatase inhibitors and selective estrogen receptor modulators remains a major treatment challenge. SERDs offer a differentiated approach by binding to and promoting degradation of the estrogen receptor, potentially addressing resistance mechanisms.
• Growing Adoption of Oral SERDs: The development of oral SERDs is improving treatment convenience compared with injectable or intramuscular endocrine therapies. The recent approval of AstraZeneca’s ETCAMAH (camizestrant) is further strengthening the shift toward oral SERDs in hormone receptor-positive, HER2-negative advanced breast cancer.
• Expansion of SERDs Into Earlier Lines of Therapy: Clinical development is increasingly evaluating SERDs in earlier treatment settings and in combination with other targeted therapies. Successful results could expand their use beyond heavily pretreated or advanced disease.
• Combination With Targeted Cancer Therapies: SERDs are being investigated alongside CDK4/6, PI3K, AKT, and other targeted inhibitors to improve treatment outcomes. These combination strategies are broadening the potential role of SERDs within precision oncology.
• Launch of Emerging SERD Drugs: The dynamics of the SERD market are expected to change in the coming years due to the launch of emerging therapies such as Palazestrant (Olema Pharmaceuticals), Giredestrant (Roche), Borestrant (EnhancedBio/Zenopharm), D-0502 (Inventis Bio), (Z)-Endoxifen (Atossa Therapeutics), HRS-8080 (Hengrui Medicine), SIM0270 (Simcere), AND019 (Kind Pharmaceuticals), and others.

Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, said that the SERD market is indeed growing, with camizestrant and imlunestrant leading the way. This creates a significant opportunity for other players like Roche, which is developing giredestrant, an upcoming SERD.

SERD Market Analysis

• Elacestrant became the first oral SERD to receive regulatory approval in the modern SERD era, introducing a new treatment option for patients with ESR1-mutated, ER+/HER2− advanced or metastatic breast cancer (mBC) following endocrine therapy. 
• The therapeutic class is now entering a more competitive phase with the recent approvals of imlunestrant and AstraZeneca’s camizestrant, further expanding the SERD treatment landscape and its commercial potential.
• The SERD landscape is shifting from injectable fulvestrant toward oral, next-generation estrogen receptor degraders, reflecting the need for more convenient endocrine treatment options and improved management of endocrine-resistant ER+/HER2− breast cancer. 
• Recent market growth has been driven by elacestrant and imlunestrant, both of which are positioned for ESR1-mutated advanced or metastatic disease.
• A major challenge for SERDs remains the ability to demonstrate meaningful clinical benefits over established endocrine therapy and CDK4/6 inhibitor regimens, particularly in earlier lines of treatment. 
• Biomarker-based patient selection will therefore be critical, with the identification of emergent ESR1 mutations expected to play an important role in optimizing treatment efficacy and supporting broader adoption of SERDs.
• Despite recent regulatory advances, the SERD class continues to face substantial late-stage development risk. 
• Amcenestrant and giredestrant failed to meet their primary endpoints in Phase III trials, while camizestrant did not demonstrate a statistically significant improvement in PFS in SERENA-4. 
• These outcomes underscore the difficulty of establishing superiority over established endocrine therapy/CDK4/6 inhibitor combinations.
• The emerging SERD pipeline includes several notable candidates, including giredestrant from Roche, palazestrant from Olema Pharmaceuticals, borestrant from EnhancedBio/Zenopharm, and D-0502 from Inventis Bio, among others.

Learn more about best SERD for ER-positive metastatic breast cancer @ Oral SERD Breast Cancer

SERD Competitive Landscape

Some of the SERD drugs under development include Palazestrant (Olema Pharmaceuticals), Giredestrant (Roche), Borestrant (EnhancedBio/Zenopharm), D-0502 (Inventis Bio), (Z)-Endoxifen (Atossa Therapeutics), HRS-8080 (Hengrui Medicine), SIM0270 (Simcere), AND019 (Kind Pharmaceuticals), and others.

Roche’s Giredestrant is an investigational selective estrogen receptor degrader (SERD) designed to completely inhibit estrogen receptor signaling while achieving robust receptor occupancy. Estrogen promotes the proliferation of hormone receptor-positive breast cancer cells by binding to estrogen receptors. Giredestrant is currently being investigated across multiple settings, including first-line (1L) ER+/HER2– metastatic breast cancer, 1L ER-positive/HER2-positive breast cancer, 1L endocrine therapy-resistant ER+/HER2– breast cancer, adjuvant ER+ breast cancer, endometrial cancer, and ovarian cancer.

Olema Pharmaceuticals’ Palazestrant (OP-1250) is a novel, orally administered small molecule that combines complete estrogen receptor antagonist (CERAN) and SERD activities. It is currently being evaluated in patients with recurrent, locally advanced, or metastatic ER+/HER2– breast cancer. The U.S. FDA has granted Fast Track designation (FTD) to palazestrant for the treatment of ER+/HER2– metastatic breast cancer. The therapy is being assessed as a monotherapy in the ongoing pivotal Phase III OPERA-01 trial and in combination with ribociclib in the pivotal Phase III OPERA-02 trial.

EnhancedBio/Zenopharm’s Borestrant is a first-in-class, small-molecule, steroidal oral SERD under clinical development for patients with ER+/HER2– locally advanced or metastatic breast cancer. It is currently being evaluated in a Phase I/II clinical trial in patients with ER+/HER2– locally advanced or metastatic breast cancer.

The anticipated launch of these emerging therapies are poised to transform the SERD market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the SERD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about oral SERD, visit @ Oral SERD Drugs

Recent Developments in the SERD Market

• In September 2026, AstraZeneca’s camizestrant in combination with CDK 4/6 inhibitor had been approved in the US for the treatment of adult patients with HR+, HER2–, locally advanced or metastatic breast cancer upon detection of ESR1 mutation and without disease progression during 1L endocrine therapy
• In June 2026, Roche announced that the US FDA had accepted the company’s NDA under Priority Review for giredestrant as an adjuvant treatment for adults with ER+/HER2–, stage I, II, and III breast cancer. The FDA is expected to make a decision on the approval by 30 November 2026
• In May 2026, Olema Pharmaceuticals anticipated to report top-line data from the pivotal Phase III (OPERA-01) of palazestrant as a monotherapy in 2L and 3L ER+/HER2– metastatic breast cancer in 2026
• In April 2026, Olema Pharmaceuticals announced new preclinical data for palazestrant alone. The data was presented in the poster presentation at the American Association for Cancer Research (AACR) Annual Meeting
• In February 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved imlunestrant for the treatment for adult patients with a certain type of breast cancer that is locally advanced or has spread to other parts of the body (metastatic) and has not responded, or has progressed further, following at least one line of hormonal treatment

SERD Epidemiology Segmentation

The SERD market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2022–2036 across the leading markets. In Germany, endometrial cancer accounted for approximately 10,800, highest among the EU4 countries.

The SERD target patient pool is segmented into:

• Total Incident Cases of Selected Indications for SERD
• Total Eligible Patient Pool for SERD
• Total Treated Cases in Selected Indications for SERD

Scope of the SERD Market Report

• SERD Patient Population Forecast
• SERD Therapeutics Market Size
• SERD Pipeline Analysis
• SERD Market Size and Trends
• SERD Market Opportunity
• SERD Market Unmet Needs
• KOL’s Views on SERD
• SERD Market Access and Reimbursement

Discover SERD medicine latest developments 2026 @ SERD Clinical Trials

Table of Contents

Related Reports

PROTAC Market

PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key PROTAC targeting therapies companies, including Pfizer, Arvinas, Celgene, Bristol Myers Squibb, Hinova Pharmaceuticals, and others.

Metastatic HER2-Positive Breast Cancer Market

Metastatic HER2-Positive Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic HER2-positive breast cancer companies including Byondis, Roche, Ambrx, Zymeworks, Jazz Pharmaceuticals, Pfizer, and others.

Metastatic HR+/HER2− Breast Cancer Market

Metastatic HR+/HER2− Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key breast cancer companies including Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, and others.

Breast Cancer Market

Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key breast cancer companies including Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, Daiichi Sankyo, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 
info@delveinsight.com 
+14699457679

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/serd-market-set-for-growth-during-the-forecast-period-20262036-as-astrazenecas-etcamah-approval-accelerates-adoption-of-oral-serds–delveinsight-302898191.html